JSPR vs AMGN

Amgen Inc.

(AMGN) offers the better valuation at 25. 0x trailing P/E (15. 9x forward), making it the more compelling value choice. Analysts rate Amgen Inc. (AMGN) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Amgen Inc.

(AMGN) delivered a total return of +65. 2%, compared to -99. 5% for Jasper Therapeutics, Inc. (JSPR). Over 10 years, the gap is even starker: AMGN returned +178. 4% versus JSPR's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 53β versus Jasper Therapeutics, Inc. 's 1. 85β — meaning JSPR is approximately 251% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Jasper Therapeutics, Inc. (JSPR) carries a lower debt/equity ratio of 30% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Amgen Inc.

grew EPS 88. 2% year-over-year, compared to 19. 2% for Jasper Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus 0. 0% for Jasper Therapeutics, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus 0. 0% for JSPR. At the gross margin level — before operating expenses — AMGN leads at 70. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, AMGN (2.

7% yield) pays a dividend. JSPR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 53), 2. 7% yield, +178. 4% 10Y return). Jasper Therapeutics, Inc. (JSPR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMGN: +178. 4%, JSPR: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

AMGN pays a dividend while JSPR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.